|
|
Volumn 27, Issue 7, 2016, Pages 1353-1354
|
|
Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLASE;
INFLIXIMAB;
IPILIMUMAB;
MESALAZINE;
MYCOPHENOLATE MOFETIL;
PEMBROLIZUMAB;
PREDNISOLONE;
TRIACYLGLYCEROL LIPASE;
IMMUNOLOGICAL ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
PDCD1 PROTEIN, HUMAN;
PROGRAMMED DEATH 1 RECEPTOR;
ACUTE PANCREATITIS;
ANTIANGIOGENIC THERAPY;
ARTICLE;
AUTOIMMUNE COLITIS;
AUTOIMMUNE DISEASE;
AUTOIMMUNE PANCREATITIS;
BRAIN VASCULITIS;
CLINICAL ARTICLE;
COLITIS;
COLON RESECTION;
CROHN DISEASE;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
ENDOCRINE DISEASE;
HUMAN;
IMMUNOPATHOLOGY;
IMMUNOSUPPRESSIVE TREATMENT;
MELANOMA;
MULTIPLE CYCLE TREATMENT;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
RETROSPECTIVE STUDY;
SIDE EFFECT;
STEROID THERAPY;
TREATMENT DURATION;
ANTAGONISTS AND INHIBITORS;
CHEMICALLY INDUCED;
PATIENT SAFETY;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;
AUTOIMMUNE DISEASES;
HUMANS;
IPILIMUMAB;
PATIENT SAFETY;
PROGRAMMED CELL DEATH 1 RECEPTOR;
RETROSPECTIVE STUDIES;
TREATMENT OUTCOME;
|
|
EID: 84977117279
PISSN: 09237534
EISSN: 15698041
Source Type: Journal
DOI: 10.1093/annonc/mdw128 Document Type: Letter |
|
Times cited : (13)
|
|
References (5)
|
